PERTH, Australia – Australian stem cell therapy company Mesoblast Ltd. said its allogeneic mesenchymal stem cell candidate, MSC-100-IV (remestemcel-L), met the primary endpoint in a phase III trial in children with refractory acute graft-vs.-host disease (aGVHD).